MedTrace Logo

Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis

NCT01850966 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2747

Last updated 2018-11-05

No results posted yet for this study

Summary

To investigate the safety and efficacy of the administration of Iguratimod (CRM01T) for 52 weeks in patients with rheumatoid arthritis in clinical practice

Conditions

Interventions

DRUG

Iguratimod

The usual adult dosage for oral use of 25 mg tablet of iguratimod once daily for 4 weeks or more, after which the dosage should be increased to one 25 mg tablet taken twice daily.

Sponsors & Collaborators

  • Eisai Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Akiko Yoshimura · Drug Fostering and Evolution Coordination Department, Eisai Co., Ltd.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-12
Primary Completion
2014-04-13
Completion
2014-04-13

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01850966 on ClinicalTrials.gov